Overview

Interest of Gentamicin-induced Readthrough in Cystic Fibrosis Patients

Status:
Terminated
Trial end date:
2005-06-01
Target enrollment:
0
Participant gender:
All
Summary
Suppression of stop mutations in the CFTR gene with parenteral gentamicin can be predicted in vitro and is associated with clinical benefit and significant modification of the CFTR-mediated chloride transport in nasal and sweat gland epithelium.
Phase:
Phase 2
Accepts Healthy Volunteers?
No
Details
Lead Sponsor:
Assistance Publique - Hôpitaux de Paris
Treatments:
Gentamicins
Criteria
Inclusion Criteria:

- cystic fibrosis with CFTR codon stop mutations

Exclusion Criteria:

- Rhinitis

- nasal polyposis

- passive or active smoking

- modification of basal treatments within the previous month

- treatments with aminoglycosides within three previous months